Floatz logo

Bempegaldesleukin

HR+/HER2- Breast Cancer

Nektar Therapeuticsprotein_peptidePhase 1/2Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the HR+/HER2- Breast Cancer cohort.

Asset / SponsorPhaseRating
Zoladex
BeOne Medicines
Phase 4BB
FULVESTRANT
BeOne Medicines
Phase 4BB
Ribociclib
BeOne Medicines
Phase 4BB
Elacestrant
West German Study Group
Phase 3BB
Letrozole
Universitaire Ziekenhuizen KU Leuven
Phase 4BB

View all 22 →

Same molecule, other indications

Bempegaldesleukin is also rated in:

melanomaDormant
CC
Indicative ·
46 / 100
View asset →
cutaneous melanomaDormant
CC
Indicative ·
46 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →